High Growth Tech Stocks to Watch in October 2024

In This Article:

The United States market has been flat over the last week, but it has seen a significant rise of 34% over the past 12 months, with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that not only demonstrate strong revenue potential and innovation but also align well with these promising market conditions.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.86%

27.98%

★★★★★★

Sarepta Therapeutics

23.58%

44.12%

★★★★★★

TG Therapeutics

28.39%

43.54%

★★★★★★

Invivyd

42.91%

70.39%

★★★★★★

Ardelyx

27.19%

66.44%

★★★★★★

Amicus Therapeutics

20.32%

62.37%

★★★★★★

AsiaFIN Holdings

60.53%

81.55%

★★★★★★

Travere Therapeutics

26.51%

69.33%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 252 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Iovance Biotherapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Iovance Biotherapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing cell therapies for metastatic melanoma and other solid tumor cancers in the United States, with a market cap of $2.84 billion.

Operations: Iovance Biotherapeutics generates revenue primarily from its therapies using autologous tumor infiltrating lymphocytes (TIL), amounting to $32.77 million. The company is focused on the treatment of metastatic melanoma and other solid tumor cancers in the U.S.

Iovance Biotherapeutics has demonstrated significant strides in revenue growth, with a reported increase from $0.238 million to $31.11 million year-over-year for Q2 2024. This surge of 45.3% per annum is anticipated to outpace the US market's average, setting a robust trajectory compared to the broader industry's growth rate of 8.7%. Moreover, earnings are expected to climb by 66.28% annually, reflecting an optimistic outlook despite current unprofitability and shareholder dilution over the past year. The company's recent presentations at high-profile healthcare conferences underscore its active engagement with the investor community and commitment to transparency during pivotal growth phases.

NasdaqGM:IOVA Revenue and Expenses Breakdown as at Oct 2024
NasdaqGM:IOVA Revenue and Expenses Breakdown as at Oct 2024

Fair Isaac

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Fair Isaac Corporation specializes in developing analytic, software, and digital decisioning technologies that help businesses automate and enhance decision-making processes globally, with a market cap of $46.97 billion.